Recent studies have shown a reduction in overall cigarette usage for individuals using the nicotine vaccine (NicVAX), which is currently under the development of Nabi Biopharmaceuticals. The nicotine vaccine has been shown to lessen the amount of nicotine available to bind to nicotinic acetylcholine receptors in the brain, decreasing the rate and amount of nicotine crossing the blood brain barrier into the brain, and ultimately reducing the urge to smoke cigarettes. A recent study, published in the American Journal of Psychiatry, evaluated the effects of the nicotine vaccine. The study included 11 smokers who smoked at a rate of 19 cigarettes per day for approximately 10 years. According to the results, the use of the nicotine vaccine by nicotine dependent individuals demonstrated a 12.5% decrease in nicotine binding to nicotinic acetylcholine receptors, 23.6% decrease in the amount of nicotine available to cross the blood-brain barrier, and a 40% overall decrease in cigarette usage for participants. To learn more about this new research, click on the link below.